Zinc's Role in Prostate Cancer and Metallothionein Expression
Author Information
Author(s): Wei Hua, Desouki Mohamed Mokhtar, Lin Shufei, Xiao Dakai, Franklin Renty B, Feng Pei
Primary Institution: Department of Biomedical Sciences, Dental School, University of Maryland at Baltimore
Hypothesis
The study aims to investigate the expression of metallothioneins in response to zinc treatment in prostate cells.
Conclusion
The study suggests that metallothioneins 1 and 2 could serve as biomarkers for prostate cancer and that zinc may be beneficial in its prevention and treatment.
Supporting Evidence
- Zinc treatment significantly increased MT1/2 expression in prostate cancer cells.
- MT1/2 levels were found to be significantly lower in malignant prostate tissues compared to normal tissues.
- The study identified a 95% reduction of MT1/2 in malignant PC-3 cells compared to normal prostate cells.
Takeaway
This study found that zinc helps increase certain proteins in prostate cells that could be important for fighting cancer.
Methodology
The study used immunohistochemistry, fluorescence staining, Western blot analysis, and RT-PCR to assess metallothionein expression in prostate cells and tissues.
Limitations
The study is limited by the small sample size and the focus on specific cell lines.
Participant Demographics
The study included human prostate tissues from 23 patients with varying conditions including normal, benign prostatic hyperplasia, and adenocarcinomas.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website